Physician profile
Vabhave Pal
NPI 1386933521
$1,945.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.10 · 2020: $49.51 · 2022: $584 · 2023: $1,237 · 2024: $60.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $800 · Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $800.00 |
| Food and Beverage | $497.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Incorporated | $800.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $294.07 | 2022-2023 | Zeposia |
| Abbvie INC. | $149.91 | 2020-2024 | |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| W. L. Gore & Associates, INC. | $88.88 | 2022 | |
| Janssen Biotech, INC. | $78.35 | 2022-2023 | Remicade, Simponi, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.04 | 2022-2023 | Xifaxan |
| Ardelyx, INC. | $71.56 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $67.67 | 2022-2024 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $51.95 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $34.93 | 2022 | |
| Boston Scientific Corporation | $27.36 | 2022 | |
| Redhill Biopharma INC. | $19.13 | 2023 | Movantik, Talicia, Aemcolo |
| Merck Sharp & Dohme LLC | $16.93 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $15.52 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.56 | 2020 | |
| Amgen INC. | $13.21 | 2023 | Amjevita |
| Tetraphase Pharmaceuticals, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vabhave Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.